Baxalta: A Rare Undervalued Biopharmaceutical Company By: TalkMarkets July 23, 2015 at 08:43 AM EDT Baxalta may be new, but it is no start-up company. Baxalta has estimated annual revenues of around $6 billion, and 16,000 employees. Read More >> Related Stocks: Amgen Baxter International Biogen Idec Celgene Corp Gilead Sciences